B Nebiyou Bekele

发表

Borrowing Strength with Nonexchangeable Priors over Subpopulations

P Müller, L G Leon-Novelo, B Nebiyou Bekele, 2012, Biometrics.

Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance.

Jing Xu, Satoru Kyo, Hong Jiang, 2005, Journal of the National Cancer Institute.

Monitoring late-onset toxicities in phase I trials using predicted risks.

Peter F Thall, Yuan Ji, Yu Shen, 2008, Biostatistics.

Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic Features

Stephen G Swisher, B Nebiyou Bekele, Shyam Biswal, 2010, Clinical Cancer Research.

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Mark Brandt, Susan O'Brien, B Nebiyou Bekele, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Generalizability of cancer clinical trial results

B Nebiyou Bekele, D. Bodurka, L. Elting, 2006, Cancer.

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.

Howard Colman, B Nebiyou Bekele, Mark R Gilbert, 2010, Neuro-oncology.

Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.

B Nebiyou Bekele, A. Gazdar, H. Shigematsu, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Adaptive randomization for multiarm comparative clinical trials based on joint efficacy/toxicity outcomes.

Yuan Ji, B Nebiyou Bekele, 2009, Biometrics.

Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice

B Nebiyou Bekele, Jeffrey N Myers, Seungwon Kim, 2006, Clinical Cancer Research.

Murine Lung Tumor Measurement Using Respiratory-Gated Micro-Computed Tomography

B Nebiyou Bekele, Dianna D Cody, Roger E Price, 2005, Investigative radiology.

A Bayesian Approach to Jointly Modeling Toxicity and Biomarker Expression in a Phase I/II Dose‐Finding Trial

Yu Shen, B Nebiyou Bekele, Yu Shen, 2005, Biometrics.

Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation.

Yuan Ji, B Nebiyou Bekele, Yisheng Li, 2008, Statistics in medicine.

Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers.

Li Mao, B Nebiyou Bekele, Fadlo R Khuri, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A modified toxicity probability interval method for dose-finding trials.

Yuan Ji, Ping Liu, B Nebiyou Bekele, 2010, Clinical trials.

Cyclic AMP response element-binding protein overexpression: a feature associated with negative prognosis in never smokers with non-small cell lung cancer.

Mi-Kyoung Kim, B Nebiyou Bekele, Scott M Lippman, 2008, Cancer research.